# US 2024/0002858 A1 · Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002858 A1
- Document ID: US20240002858A1
- Status: Published application
- Kind: A1
- Application number: 18/213,289
- Filed: 2023-06-23
- Published: 2024-01-04
- Earliest claimed: 2022-06-24
- Assignees: Novo Nordisk A/S; Dicerna Pharmaceuticals, Inc.
- Applicants: Novo Nordisk A/S; Dicerna Pharmaceuticals, Inc.
- Inventors: Anna Linda Blois; Christina Marie Priest; Jihye Park; Henryk Dudek
- Web page: https://patentgrep.com/patent/US20240002858A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/531: Stem-loop; Hairpin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.

## Claims

### Claim 1

An RNAi oligonucleotide for reducing transmembrane serine protease 6 (TMPRSS6) expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex region, and wherein the sense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 844 and the antisense strand comprises the nucleotide sequences as set forth in SEQ ID NO: 600.

### Claim 2 (depends on 1)

The RNAi oligonucleotide according to claim 1, wherein the sense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 579.

### Claim 3 (depends on 1)

The RNAi oligonucleotide according to claim 1, wherein the sense strand proximal the 3′ end comprises a stem-loop set forth as S1-Lp-S2, wherein S1 is complementary to S2, and wherein Lp forms a loop of 3-5 nucleotides in length between S1 and S2.

### Claim 4 (depends on 2)

The RNAi oligonucleotide according to claim 2, wherein the sense strand proximal the 3′ end comprises a stem-loop set forth as S1-Lp-S2, wherein S1 is complementary to S2, and wherein Lp forms a loop of 4 nucleotides in length between S1 and S2.

### Claim 5 (depends on 4)

The RNAi oligonucleotide according to claim 4, wherein the oligonucleotide comprises at least one modified nucleotide.

### Claim 6 (depends on 4)

The RNAi oligonucleotide according to claim 4, wherein all nucleotides of the oligonucleotide are modified nucleotides.

### Claim 7 (depends on 6)

The RNAi oligonucleotide according to claim 6, wherein all nucleotides of the oligonucleotides are modified, and each one of the modified nucleotides is 2′-fluro or 2′-O-methyl.

### Claim 8 (depends on 7)

The RNAi oligonucleotide according to claim 7, wherein
the sense strand comprises 36 nucleotides and the antisense strand comprises 22 nucleotides, the nucleotides of each one of the strands being numbered 5′ to 3′;
all of positions 1-7, 12-27, and 31-36 of the sense strand and positions 1, 6, 8, 9, 11-13, and 15-22 of the antisense strand comprise a 2′-O-methyl (2′-OMe) modification; and
all of positions 8-11 of the sense strand and 2, 3, 4, 5, 7, 10 and 14 of the antisense strand comprise a 2′-fluoro (2′-F) modification.

### Claim 9 (depends on 4)

The RNAi oligonucleotide according to claim 4, wherein at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands.

### Claim 10 (depends on 8)

The RNAi oligonucleotide according to claim 8, wherein at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands.

### Claim 11 (depends on 9)

The RNAi oligonucleotide according to claim 9, wherein each targeting ligand comprises a N-acetylgalactosamine (GalNAc) moiety.

### Claim 12 (depends on 10)

The RNAi oligonucleotide according to claim 10, wherein each targeting ligand comprises a N-acetylgalactosamine (GalNAc) moiety.

### Claim 13 (depends on 4)

The RNAi oligonucleotide according to claim 4, wherein the second, third and fourth nucleotides of the loop Lp from 5′ to 3′ are each conjugated to a monovalent N-acetylgalactosamine (GalNAc) moiety.

### Claim 14 (depends on 8)

The RNAi oligonucleotide according to claim 8, wherein the second, third and fourth nucleotides of the loop Lp from 5′ to 3′ are each conjugated to a monovalent N-acetylgalactosamine (GalNAc) moiety.

### Claim 15 (depends on 8)

The RNAi oligonucleotide according to claim 8, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

### Claim 16 (depends on 14)

The RNAi oligonucleotide according to claim 14, wherein the oligonucleotide comprises at least one phosphorothioate linkage.

### Claim 17 (depends on 15)

The RNAi oligonucleotide according to claim 15, wherein
the antisense strand comprises 22 nucleotides;
the nucleotides of each one of the strands are numbered 5′ to 3′; and
a phosphorothioate linkage is provided between positions 1 and 2 of the sense strand, and between positions 1 and 2, between positions 2 and 3, between positions 3 and 4, between positions 20 and 21 and between positions 21 and 22 of the antisense strand.

### Claim 18 (depends on 16)

The RNAi oligonucleotide according to claim 16, wherein
the antisense strand comprises 22 nucleotides;
the nucleotides of each one of the strands are numbered 5′ to 3′; and a phosphorothioate linkage is provided between positions 1 and 2 of the sense strand, and between positions 1 and 2, between positions 2 and 3, between positions 3 and 4, between positions 20 and 21 and between positions 21 and 22 of the antisense strand.

### Claim 19 (depends on 17)

The RNAi oligonucleotide according to claim 17, wherein a 5′-terminal nucleotide of the antisense strand comprises a structure according to Chem. 1a (MePhosphonate-4O-mU):

### Claim 20 (depends on 18)

The RNAi oligonucleotide according to claim 18, wherein a 5′-terminal nucleotide of the antisense strand comprises a structure according to Chem. 1a (MePhosphonate-4O-mU):

### Claim 21 (depends on 14)

The RNAi oligonucleotide according to claim 14, wherein the antisense strand comprises a 3′ overhang of 5′-GG-3′.

### Claim 22 (depends on 20)

The RNAi oligonucleotide according to claim 20, wherein the antisense strand comprises a 3′ overhang of 5′-GG-3′.

### Claim 23

An RNAi oligonucleotide for reducing TMPRSS6 expression, the oligonucleotide comprising a sense strand and an antisense strand, wherein
the sense strand comprises the sequence and all of the modifications of 5′-[mGs][mG][mU][mG][mC][mU][mA][fC][fU][fC][fU][mG][mG][mU][mA][mU][mU][mU][mC][mA][mG][mC]
[mA][mG][mC][mC][mG][ademA-GalNAc][ademA-GalNAc][ademA-GalNAc][mG][mG][mC][mU][mG][mC]-3′ (SEQ ID NO: 621), and
wherein the antisense strand comprises the sequence and all of the modifications of 5′-[MePhosphonate-4O-mUs][fGs][fAs][fA][fA][mU][fA][mC][mC][fA][mG][mA][mG][fU][mA][mG][mC][mA][mC][mCs][m Gs][mG]-3′ (SEQ ID NO: 642), wherein mC, mA, mG, mU=2′-OMe ribonucleosides; fA, fC, fG, fU=2′F ribonucleosides; s=phosphorothioate, and wherein ademA-GalNAc=

### Claim 24 (depends on 23)

A pharmaceutical composition comprising the RNAi oligonucleotide according to claim 23, and a pharmaceutically acceptable carrier, delivery agent or excipient.

### Claim 25 (depends on 23)

A method of treating hemochromatosis, comprising administering to a patient in need thereof the RNAi oligonucleotide of claim 23.

### Claim 26 (depends on 25)

The method of claim 25, wherein the hemochromatosis is hereditary hemochromatosis or beta-thalassemia.

### Claim 27 (depends on 24)

A method of treating hemochromatosis, comprising administering to a patient in need thereof the pharmaceutical composition of claim 24.

### Claim 28 (depends on 27)

The method of claim 27, wherein the hemochromatosis is hereditary hemochromatosis or beta-thalassemia.
